Kanaly Trust’s Teva Pharmaceuticals TEVA Stock Holding History

Kanaly Trust’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$105K	Sell	2,900 -684	-19%	-$27.3K	0.02%	200
2016 Q3	$165K	Sell	3,584 -1,751	-33%	-$91.4K	0.04%	161
2016 Q2	$268K	Sell	5,335 -93	-2%	-$4.95K	0.05%	127
2016 Q1	$290K	Sell	5,428 -77	-1%	-$4.52K	0.06%	119
2015 Q4	$361K	Sell	5,505 -47	-0.8%	-$2.9K	0.07%	110
2015 Q3	$313K	Sell	5,552 -59	-1%	-$3.83K	0.07%	113
2015 Q2	$332K	Buy	5,611 +1,363	+32%	+$84.1K	0.07%	124
2015 Q1	$265K	Sell	4,248 -6,866	-62%	-$399K	0.05%	143
2014 Q4	$639K	Sell	11,114 -133	-1%	-$7.41K	0.13%	87
2014 Q3	$605K	Sell	11,247 -136	-1%	-$7.21K	0.12%	94
2014 Q2	$597K	Buy	11,383 +8,026	+239%	+$410K	0.11%	105
2014 Q1	$177K	Sell	3,357 -428	-11%	-$19.8K	0.03%	196
2013 Q4	$152K	Buy	+3,785	New	+$149K	0.03%	211

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Kanaly Trust's TEVA Position: Q4 2016 in Review

Kanaly Trust reduced its Teva Pharmaceuticals (TEVA) stake by 19% in Q4 2016, selling an estimated $27.3K and leaving 2,900 shares worth $105K. The position accounts for 0.02% of the portfolio, ranked #200.

Kanaly Trust first reported a position in TEVA in Q4 2013 and has held it in 13 quarters since. The position peaked at $639K in Q4 2014. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Kanaly Trust held 2,900 shares of Teva Pharmaceuticals worth $105K as of Q4 2016.
Kanaly Trust sold 684 Teva Pharmaceuticals shares in Q4 2016, an estimated $27.3K.
Teva Pharmaceuticals made up 0.02% of Kanaly Trust's portfolio in Q4 2016, its #200 holding.
Kanaly Trust first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 13 quarters since.
Kanaly Trust's Teva Pharmaceuticals position peaked at $639K in Q4 2014.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Kanaly Trust's 13F filing for Q4 2016, filed 23 Jan 2017.